EUA 19 Scientific Program

October 16th, 2019
08.00 – 09.40 Oral presentations
  Moderators:
Ilhan Gecit, Turkey
Haci Mehmet Turk, Turkey
 
09.40 – 10.00 Opening remarks
  Selami Albayrak, Turkey
Gerasimos Alivizatos, Greece
M. Ihsan Karaman, Turkey
 
10.00 – 10.30 Session 1- Mechanism and Biology – Diagnosis and Treatment of Urothelial Cancer
  Moderators
Gerasimos Alivizatos, Greece
Yasar Ozgok, Turkey
10.00 – 10.15

Molecular Pathways in Urothelial Cancer – Dilek Telci, Turkey

10.15 – 10.30 Genomic Philosophy and Biomarkers for Treatment Selection in Urothelial Cancer – Peter Black, Canada
10.30 – 10.40 Discussion
10.40 – 11.20

BCG refractory diseases

10.40 – 10.50 Mechanism of Resistance to BCG – Oktay Akca, United States
10.50 – 11.00 The Clinical Impacts of Pathological Variants in BCG Response – Ioannis Varkarakis, Greece
11.00 – 11.10 Predictive Markers of BCG Response – Murat Bozlu, Turkey
11.10 – 11.20 Immunotherapy in Non-Muscle Invasive Bladder Cancer – Ozcan Yildiz, Turkey
11.20 – 11.30 Discussion
 
11.30 – 11.50 Break
 
11.50 – 12.55 Session 2- Diagnosis and Treatment of Urothelial Cancer-1
  Moderators
Nikolaos Ferakis, Greece
Ahmet Yaser Muslumanoglu, Turkey
11.50 – 12.05

Imaging Modalities in Staging Bladder Cancer Prior to Radical Cystectomy – Nathan Lawrentschuk, Australia

12.05 – 12.25

Debate: The Optimal Local Treatment for Muscle Invasive Bladder Cancer

  • Trimodality treatment – Hale Caglar
  • Radical cystectomy – Oner Sanli
12.05 – 12.15 Trimodality Treatment – Discussant: Hale Basak Caglar, Turkey
12.15 – 12.25 Radical Cystectomy – Oner Sanli, Turkey
12.25 – 12.35 Discussion
12.35 – 12.50 Robotic-Assisted Radical Cystectomy Versus Open Radical Cystectomy – Nathan Lawrentschuk, Australia
12.50 – 13.05 Biomarker-Based Approach to Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer – Peter Black, Canada
 
13.05 – 13.45 Lunch
 
13.45 – 14.30 Case Panel Discussion: Challenging Cases in Bladder Cancer
  Moderator: Tarik Esen, Turkey
Panelists
Hale Basak Caglar, Turkey
Abdurrahman Isikdogan, Turkey
Nathan Lawrentschuk, Australia
Ozgur Ozyilkan, Turkey
Altug Tuncel, Turkey
 
14.30 – 15.45 Session 3- Diagnosis and Treatment of Urothelial Cancer-2
  Moderators
Eyup Gumus, Turkey
Abdurrahim Imamoglu, Turkey
Ozgur Ozyilkan, Turkey
14.30 – 14.45 What Is the Ideal Time to Start Immunotherapy in Metastatic Muscle Invasive Bladder Cancer? – Mehmet Artac, Turkey
14.45 – 15.15

How Can We Improve the Functional Outcomes in Radical Cystectomy?

14.45 – 14.55 (Is still) Prostate Sparing Approach – Yilmaz Aslan, Turkey
14.55 – 15.05 Robotic Nerve Sparing Radical Cystectomy – Why Do I Recommend? – Ali Fuat Atmaca, Turkey
15.05 – 15.15 Open Nerve Sparing Radical Cystectomy – Ozdal Dillioglugil, Turkey
15.15 – 15.25 Discussion
15.25 – 15.45 Debate: Debate: Is There a Role of Metastasectomy in Urothelial Cancer?
  • Pro: Selcuk Sahin, Turkey
  • Con: Fatih Kose, Turkey
 
15.45 – 16.05 Break
 
16.05 – 17.05 Best Posters in EUA 2019
  Moderators
Mahmut Gumus, Turkey
Ali Ihsan Tasci, Turkey
 
17.05 – 17.25 B2B Session in EUA 2019
  Moderators
Archil Chkhotua, Georgia
Basak Oven, Turkey
17.05 – 17.25

Variants and New Entities of Bladder Cancer – Gozde Kir, Turkey

17.25 – 18.00 Hot Topics and Clinical Reflections
17.25 – 17.35 Bladder Cancer – Emrah Yuruk, Turkey
17.35 – 17.45

Metastatic Prostate Cancer – Fatih Selcuk Biricik, Turkey

17.45 – 17.55

Renal Cancer – Volkan Tugcu, Turkey

 

October 17th, 2019
07.15 – 16.35 World Urological Oncology Federation Symposium

 

Chair: Laurence Klotz, Canada

07:15 – 07:45

Meet and Greet International Colleagues – Coffee served. For WUOF attendees only.

07:45 – 07:50  

Framing of Theme – Laurence Klotz, Canada

   
07:50 – 09:55 Session One. Early Detection and Treatment of Localized Prostate Cancer
  Moderators
Arturo Mendoza-Valdes, Mexico
Asif Yildirim, Turkey
07:55 – 08:10

A Epidemiologist’s View of Prostate Cancer Screening – Sigrid V. Carlsson, Sweden and United States

08:10 – 08:25

Early Detection of Prostate Cancer in a Resource Constrained Environment – Robin Roberts, Bahamas

08:25 – 08:40

The Impact of Positive Surgical Margins, Biochemical Recurrence or PSA Persistence on Oncological Outcomes after Radical Prostatectomy – Derya Tilki, Germany/United States

08:40 – 08:55

Retzius Sparing RP: Is it Beneficial? – Ben Challacombe, United Kingdom

08:55 – 09:10

nmCRPC – Does It Exist? – Boris Hadaschik, Germany

09:10 – 09:15

Discussion

09:10 – 09:30

Strengths and Limitations of PSMA PET – Damien Bolton, Australia

09:30 – 09:50 Debate: Does RP Have a Role in the Management of Oligomets?
  • Pro: R. Jeffrey Karnes, United States
  • Con: Ozdal Dillioglugil, Turkey
09:50 – 09:55

Discussion

   
09:55 – 11:10 Session Two. Prostate Cancer Management Options
  Moderators
Shrawan Kumar Singh, India
Ofer Yossepowitch, Israel
10:00 – 10:15

Salvage Lymphadenectomy in the PSMA Era: Where to Draw the Line? – Axel Heidenreich, Germany

10:15 – 10:30

The Phenomenology and Epistemology of the Androgen Receptor – Bertrand Tombal, Belgium

10:30 – 10:45

Timing of ADT in the Era of Stampede and Latitude – Mehmet Ali Nahit Sendur, Turkey

10:45 – 11:00

Chemotherapy and ARATs vs Metastases-Directed Therapy for mHSPC – Markus Graefen, Germany

11:00 – 11:10 

Discussion

   
11:10 – 12:40 Session Three. Renal Cancer
  Moderators
Alexandra Colquhoun, United Kingdom
Mark Frydenberg, Australia
11:15 – 11:30 

Cytoreductive Nephrectomy — Has it Had Its Day? – Alessandro Volpe, Italy

11:30 – 11:45

Management of RCC Caval Thrombus in 2019 – Amlesh Seth, India

11:45 – 12:00

Adjuvant Therapy for High Risk RCC: Current Status – Shomik Sengupta, Australia

12:00 – 12:15

Active Surveillance for Small Renal Masses: Where to Draw the Line? – Ricardo Rendon, Canada

12:15 – 12:25

Discussion

12:25 – 12:40

SPECIAL LECTURE: POWER POINT 101. Fumble at the Goal Line: How Presenters Hijack Attention and Lose Their Audience – Michael Leveridge, Canada

   
12:40 – 13:05 Working Lunch
Meal voucher required. Complimentary meal to all seated participants attending Session Four Working Lunch.
   
13.05 – 13:25 Session Four | The Internationals
  Moderators
Jean de la Rosette, Turkey
Laurence Klotz, Canada
13:05 – 13:10

Introduction
Laurence Klotz, Canada
The 2019 ICUD: Biomarkers in Urologic Oncology

13:10 – 13:20

History and Impact of ICUDs – Luc Valiquette, Canada

13:20 – 13:25

Current WUOF-SIU-ICUD Initiative and How to Get Involved – Laurence Klotz, Canada

   
13:25 – 15:15 Session Five. Town Hall – Innovation and the Molecular Revolution
  Moderators
Jean de la Rosette, Turkey
Laurence Klotz, Canada
13:30 – 13:45

Special Guest Lecture: How to Ensure Innovation in Urologic Oncology? – Joseph A. Smith, United States

13:45 – 13:50

Discussion

13:50 – 14:50

Panel. How to Ensure Innovation: Urologist & Industry Perspectives
Calvin Chao, United States
Panelists
Michael Bates, Australia
Peter Black, Canada
Peter Carroll, United States
Christopher Evans, United States

14:50 – 15:10

Open Discussion

   
15:15 – 15:35 Session Six. Germ Cell Tumours
  Moderators
Badrinath Konety, United States
Nathan Lawrentschuk, Australia
15:20 – 15:35

Update on the Management of Complex Germ Cell Tumors – Sia Daneshmand, United States

   
15:35 – 16:35  Session Seven. Advanced Prostate Cancer Treatment Options

15:40 – 15:55

Role of Estrogen in the Management of Prostate Cancer – Leonardo O. Reis, Brazil

15:55 – 16:10

Theranostic Application of PSMA-Labeled Lutetium-177 – Tarik Esen, Turkey

16:10 – 16:25

Translational Approaches to Targeting the Androgen Axis in CRPC – Christopher Evans, United States

16:25 – 16:35

Discussion

16:35 – 16:35

Adjourn

 

October 18th, 2019
08.00 – 09.30 Session 4 – Metastatic Prostate Cancer
  Moderators
Atif Akdas, Turkey
Theodoros Kalogeropoulos, Greece
08.00 – 08.15

Characteristics and Structural Variations of Genome in Metastatic Prostate Cancer – Christopher Evans, United States

08.15 – 08.30

The Role of PET-CT in Metastatic Prostate Cancer – What Urologists Think? – Konstantinos Stravodimos, Greece

08.30 – 09.00

Improving Outcome and Reducing Morbidity with ADT – Laurence Klotz, Canada

09.00 – 09.15

Current Status of Theranostics in Prostate Cancer – Meltem Caglar Tuncali, Turkey

09.15 – 09.30

Role of Immunotherapy in mCRPC: A New Hope – Timucin Cil, Turkey

 
09.30 – 10.10 Session 5 – Oligometastatic Prostate Cancer
  Moderators
Selami Albayrak, Turkey
Jean de la Rosette, Turkey
Bulent Orhan, Turkey
09.30 – 09.40 Urologists’ Perspective – Faruk Ozcan, Turkey
09.40 – 09.50 Oncologists’ Perspective – Fuat Demirelli, Turkey
09.50 – 10.00 Radiation Oncologists’ Perspective – Hale Basak Caglar, Turkey
10.00 – 10.10 Discussion
 
10.10 – 10.30 Coffee Break
 
10.30 – 11.30 Challenging cases in metastatic prostate cancer – Case Panel Discussion
 

Moderators
Damien Bolton, Australia
Laurence Klotz, Canada

Panelists
Bulent Akduman, Turkey
Cagatay Arslan, Turkey
Fatih Atug, Turkey
Metin Ozkan, Turkey
Meltem Caglar Tuncali, Turkey

 
11.30 – 13.00 Session 6 – Renal Cancer: Locally Advanced and Metastatic
  Moderators
Turhan Caskurlu, Turkey
Salim Basol Tekin, Turkey
11.30 – 11.50

Fraility in RCC – Selcuk Guven, Turkey

11.50 – 12.10 Situation after CARMENA
11.50 – 12.00

Situation After CARMENA: Urologists’ Perspective – Pilar Laguna, Turkey

12.00 – 12.10

Situation After CARMENA: Oncologists’ Perspective – Umut Kefeli, Turkey

 
12.10 – 13.00 Challenging cases in RCC
  Moderator: Pilar Laguna, Turkey
Panelists
Yigit Akin, Turkey
Faysal Dane, Turkey
Mehmet Kucukoner, Turkey
Omer Levent Tuncay, Turkey